What does BI-RADS classification mean?
The American Radiological Association established the Breast Imaging Reporting and Data System (BI-RADS) in order to standardize the evaluation of mammogram images. This classification is currently used in the fourth edition of BI-RADS, 2003, and is also used for ultrasound and MRI reports.
Diagnostic grading of the 2003 American Radiological Association Breast Imaging Reporting and Data System
Grade 0: Additional imaging is required.
Grade 1: Negative
Grade 2: Benign. Includes fibroadenomas that have calcified, multiple secretory calcifications, lesions with a fat component, intra-breast lymph nodes, and implanted prostheses.
Grade 3: Probably benign, short-term follow-up observation is recommended. (The likelihood of malignancy is less than 2%. Short-term follow-up generally refers to six months.) Includes non-calcified well-defined masses and clusters of punctate calcifications Grade 4: suspicious for malignancy, biopsy is recommended.
Grade 5: highly suggestive of malignancy and should be treated appropriately. The likelihood of malignancy is greater than 95%.
Grade 6: Biopsy has confirmed malignancy.
In 2003, the American Radiological Association developed the BI-RADS for ultrasound diagnosis, modeled after the BI-RADS for mammography.
Grade 0: Additional imaging is required.
Grade 1: Negative Grade 2: Benign. Includes simple cysts, intra-mammary lymph nodes, implanted prostheses, and post-surgical changes with no change on follow-up.
Grade 3: Probably benign, short-term follow-up observation recommended. Includes lesions considered to be fibroadenomas, complex cysts, clusters of microscopic cysts.
Grade 4: Suspicious of malignancy, biopsy recommended.
Grade 5: Highly suggestive of malignancy and should be treated appropriately.
Grade 6: Biopsy has confirmed malignancy.
In 2003, the American Radiological Association developed the BI-RADS for MRI, modeled after the BI-RADS for mammography.
Grade 0: Inadequate examination, further examination is needed.
Level 1: Negative, with routine follow-up.
Level 2: benign lesion, routine follow-up.
Level 3: High probability of benign, short-term follow-up.
Follow-up interval of 3 or 6 months.
For those in the secretory phase of the menstrual cycle and taking estrogenic drugs, it is recommended to pick the early follicular phase of the menstrual cycle or stop taking drugs for a period of time for review.
Grade 4: suspicious lesion, biopsy is recommended.
Grade 5: Highly suggestive of malignancy, appropriate therapeutic measures are recommended Grade 6: Biopsy pathology confirms malignancy, appropriate therapeutic measures are recommended